Get started
Aptevo Therapeutics Inc.Aptevo Therapeutics Inc.Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

APVO chart


Full chart

APVO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.70 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−25.4476 USD
Net income (FY)
‪−17.41 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪18.50 M‬
Beta (1Y)
2.23

Employees


Employees (FY)
40
Change (1Y)
−5 −11.11%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−466.25 K‬ USD

About Aptevo Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Marvin L. White
Website
aptevotherapeutics.com
Headquarters
Seattle
Founded
2016
FIGI
BBG009RRZ8C2
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

APVO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of APVO is 0.3077 USD — it has increased by 15.33% in the past 24 hours. Watch Aptevo Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aptevo Therapeutics Inc. stocks are traded under the ticker APVO.
APVO stock has risen by 28.32% compared to the previous week, the month change is a −3.84% fall, over the last year Aptevo Therapeutics Inc. has showed a −96.58% decrease.
We've gathered analysts' opinions on Aptevo Therapeutics Inc. future price: according to them, APVO price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Watch APVO chart and read a more detailed Aptevo Therapeutics Inc. stock forecast: see what analysts think of Aptevo Therapeutics Inc. and suggest that you do with its stocks.
APVO reached its all-time high on Jul 27, 2016 with the price of 5,106.6400 USD, and its all-time low was 0.1380 USD and was reached on Oct 14, 2024. View more price dynamics on APVO chart.
See other stocks reaching their highest and lowest prices.
APVO stock is 23.03% volatile and has beta coefficient of 2.23. Track Aptevo Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Aptevo Therapeutics Inc. there?
Today Aptevo Therapeutics Inc. has the market capitalization of ‪5.70 M‬, it has increased by 26.45% over the last week.
Yes, you can track Aptevo Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Aptevo Therapeutics Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
APVO earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.57 USD resulting in a 15.79% surprise. The estimated earnings for the next quarter are −0.28 USD per share. See more details about Aptevo Therapeutics Inc. earnings.
Aptevo Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
APVO net income for the last quarter is ‪−5.10 M‬ USD, while the quarter before that showed ‪−5.88 M‬ USD of net income which accounts for 13.29% change. Track more Aptevo Therapeutics Inc. financial stats to get the full picture.
No, APVO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 40.00 employees. See our rating of the largest employees — is Aptevo Therapeutics Inc. on this list?
Like other stocks, APVO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aptevo Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aptevo Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aptevo Therapeutics Inc. stock shows the sell signal. See more of Aptevo Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.